Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome

Cancer Research

Volumn 63, Issue 1, 2003, Pages 149-153

  Hara, Takahito ^a   Miyazaki, Jun ichi ^a   Araki, Hideo ^a   Yamaoka, Masuo ^a   Kanzaki, Naoyuki ^a   Kusaka, Masami ^a   Miyamoto, Masaomi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL CULTURE; CELL GROWTH; CODON; CONTROLLED STUDY; CULTURE MEDIUM; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SURVIVAL RATE; TRANSACTIVATION; WITHDRAWAL SYNDROME;

AMINO ACID SUBSTITUTION; ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; CELL DIVISION; DISEASE MODELS, ANIMAL; DNA PRIMERS; DNA, COMPLEMENTARY; HUMANS; MALE; MICE; MICE, NUDE; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTANCE WITHDRAWAL SYNDROME; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0037226103     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Scher, H. I., Steineck, G., and Kelly, W. K. Hormone-refractory (D3) prostate cancer: refining the concept. Urology, 46: 142-148, 1995.
2. Schellhammer, P, F., Venner, P., Haas, G. P., Small, E. J., Nieh, P. T., Seabaugh, D. R., Patterson, A. L., Klein, E., Wajsman, Z., Furr, B., Chen, Y., and Kolvenbag, G. J. C. M. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J. Urol., 157: 1731-1735, 1997.
3. Scher, H. L, and Kolvenbag, G. J. C. M. The antiandrogen withdrawal syndrome in relapsed prostate cancer. Eur. Urol., 31 (Suppl. 2): 3-7, 1997.
4. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A., and Mulder, E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry, 31: 2393-2399, 1992.
5. Fenton, M. A., Shuster, T. D., Fertig, A. M., Taplin, M. E., Kolvenbag, G., Bubley, G. J., and Balk, S. P. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res., 3: 1383-1388, 1997.
6. Zhao, X. Y., Malloy, P. J., Krishnan, A. V., Swami, S., Navone, N. M., Peehl, D. M., and Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med 6: 703-706, 2000.
7. Tilley, W. D., Buchanan, G., Hickey, T, E., and Bentel, J. M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res., 2: 277-285, 1996.
8. Schuurmans, A. L. G., Bolt, J., Voorhorst, M. M., Blankenstein, R. A., and Mulder, E. Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int. J. Cancer, 42: 917-922, 1988.
9. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., and Mulder, E. A. mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 173: 534-540, 1990.
10. Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., and Klocker, H. Switch from antagonist to agonist of the androgen receptor blocker bicalutmide is associated with prostate tumor progression in a new model system. Br. J. Cancer, 81: 242-251, 1999.
11. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332: 1393-1398, 1995.
12. Marcelli, M., Ittmann, M., Mariani, S., Sutherland, R., Nigam, R., Murthy, L., Zhao, Y., DiConcini, D., Puxeddu, E., Esen, A., Eastham, J., Weigel, N. L., and Lamb, D. J. Androgen receptor mutations in prostate cancer. Cancer Res., 60: 944-949, 2000.
13. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C. B., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., and Klocker, H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol., 7: 1541-1550, 1993.
14. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B., and Balk, S. P. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res., 59: 2511-2515, 1999.
15. Haapala, K., Hyytinen, E. R., Roiha, M., Laurila, M., Rantala, I., Helin, H. J., and Koivisto, P. A. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide, Lab. Investig., 81: 1647-1651, 2001.
16. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash. DC), 293: 876-880, 2001.
17. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.